Shots:
- Regeneron has entered into an asset purchase agreement with 23andMe for $256M, strengthening Regeneron’s genetics-guided research & drug development activities
- Regeneron to acquire key assets of 23andMe, incl. Personal Genome Service, Total Health & Research Services business lines, plus its Biobank & associated assets, with services continuing uninterrupted; closing is expected in Q3’25
- 23andMe will operate as a wholly owned Regeneron subsidiary & continue its personal genomics services, although the acquisition excludes 23andMe’s Lemonaid Health business
Ref: Regeneron| Image: 23andMe | Press Release
Related News:- Regeneron’s Lynozyfic (Linvoseltamab) Receives the EC’s Conditional Approval for R/R Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
